Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chamindra G Laverty

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Pediatric Clinics of North America|July 6, 2025
Hypotonia in the Newborn InfantChamindra G Laverty
Advances in Therapy|November 11, 2024
Assessment of Phosphorodiamidate Morpholino Oligomer Treatment Patterns for Patients with Duchenne Muscular Dystrophy: A MarketScan Claims AnalysisAlexa C Klimchak, James Signorovitch, Bryan Innis, et al.
ERJ Open Research|September 27, 2023
Effectiveness of long-term noninvasive ventilation measured by remote monitoring in neuromuscular diseaseJeremy E Orr, Kenneth Chen, Florin Vaida, et al.
Journal of Multidisciplinary Healthcare|September 3, 2024
Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesRyan Fischer, Pat Furlong, Annie Kennedy, et al.
Journal of Neuromuscular Diseases|November 10, 2025
Onasemnogene abeparvovec gene therapy for treatment of patients with spinal muscular atrophy: Updated real-world practical considerationsCrystal M Proud, Elizabeth A Kichula, Susan E Matesanz, et al.
HGG Advances|February 15, 2024
Clinical, immunohistochemical, and genetic characterization of splice-altering biallelic DES variants: Therapeutic implicationsJanelle Geist Hauserman, Chamindra G Laverty, Sandra Donkervoort, et al.
Neurology|October 28, 2025
Expert Consensus on Genetic Diagnostic Approaches for Patients With Limb-Girdle Muscular DystrophyVolker Straub, Amanda R Clause, Sandra Donkervoort, et al.
JCI Insight|July 30, 2024
Missense variants in CMS22 patients reveal that PREPL has both enzymatic and nonenzymatic functionsYenthe Monnens, Anastasia Theodoropoulou, Karen Rosier, et al.
The Lancet. Neurology|March 20, 2024
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialEugenio Mercuri, Juan J Vilchez, Odile Boespflug-Tanguy, et al.
Annals of Clinical and Translational Neurology|February 9, 2025
Clinical characterization of Collagen XII-related disease caused by biallelic COL12A1 variantsRiley M McCarty, Dimah Saade, Pinki Munot, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pediatric Clinics of North America|July 6, 2025
Hypotonia in the Newborn InfantChamindra G Laverty
Advances in Therapy|November 11, 2024
Assessment of Phosphorodiamidate Morpholino Oligomer Treatment Patterns for Patients with Duchenne Muscular Dystrophy: A MarketScan Claims AnalysisAlexa C Klimchak, James Signorovitch, Bryan Innis, et al.
ERJ Open Research|September 27, 2023
Effectiveness of long-term noninvasive ventilation measured by remote monitoring in neuromuscular diseaseJeremy E Orr, Kenneth Chen, Florin Vaida, et al.
Journal of Multidisciplinary Healthcare|September 3, 2024
Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesRyan Fischer, Pat Furlong, Annie Kennedy, et al.
Journal of Neuromuscular Diseases|November 10, 2025
Onasemnogene abeparvovec gene therapy for treatment of patients with spinal muscular atrophy: Updated real-world practical considerationsCrystal M Proud, Elizabeth A Kichula, Susan E Matesanz, et al.
HGG Advances|February 15, 2024
Clinical, immunohistochemical, and genetic characterization of splice-altering biallelic DES variants: Therapeutic implicationsJanelle Geist Hauserman, Chamindra G Laverty, Sandra Donkervoort, et al.
Neurology|October 28, 2025
Expert Consensus on Genetic Diagnostic Approaches for Patients With Limb-Girdle Muscular DystrophyVolker Straub, Amanda R Clause, Sandra Donkervoort, et al.
JCI Insight|July 30, 2024
Missense variants in CMS22 patients reveal that PREPL has both enzymatic and nonenzymatic functionsYenthe Monnens, Anastasia Theodoropoulou, Karen Rosier, et al.
The Lancet. Neurology|March 20, 2024
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialEugenio Mercuri, Juan J Vilchez, Odile Boespflug-Tanguy, et al.
Annals of Clinical and Translational Neurology|February 9, 2025
Clinical characterization of Collagen XII-related disease caused by biallelic COL12A1 variantsRiley M McCarty, Dimah Saade, Pinki Munot, et al.
Pageof 2